Bleeding Events After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review.
TAVR
bleeding
transcatheter aortic valve replacement
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
21 02 2023
21 02 2023
Historique:
received:
25
10
2022
accepted:
21
11
2022
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
18
2
2023
Statut:
ppublish
Résumé
Transcatheter aortic valve replacement (TAVR) has gained over time a major reduction in procedural complications. Despite this, clinically relevant bleeding still occurs in a non-negligible proportion of patients and adversely affects prognosis. Patients with severe aortic stenosis are at heightened risk for spontaneous bleeding due to advanced age and a high comorbidity burden. Also, procedural factors and antithrombotic management contribute to define individual bleeding susceptibility. Bleeding prevention represents an emerging area for improving patient care. Because of the tight hemorrhagic/ischemic balance, a tailored approach based on individual bleeding-risk profile, such as a less invasive antithrombotic regimen or appropriate diagnostic preprocedural evaluation, should be pursued to avoid bleeding events. This review aims to provide an in-depth overview of bleeding events in the TAVR field, including definitions, timing and the extent of risk, and clinical impact, as well as updates on antithrombotic management and its potential influence on bleeding complications.
Identifiants
pubmed: 36792284
pii: S0735-1097(22)07622-7
doi: 10.1016/j.jacc.2022.11.050
pii:
doi:
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-702Informations de copyright
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Nuche has received a research grant from the “Fundación Alfonso Martín Escudero” (Madrid, Spain). Dr Rodés-Cabau has received institutional research grants and speaker/consultant fees from Edwards Lifesciences and Medtronic. Dr Rodés-Cabau holds the research chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.